Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Prosetta Biosciences Inc. is managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are all concentrated within 1 distinct art unit, indicating the technical focus for the company's current filings. The portfolio involves 2 distinct examiners, which shows the concentration of work among the reviewing staff.
RICCI, CRAIG D is the busiest examiner for the company, overseeing 2 pending office actions. This count of 2 represents a portion of the 3 total pending office actions currently in progress. With 2 examiners handling 3 actions, the workload is more concentrated than in portfolios where every action has a unique examiner, as RICCI, CRAIG D manages 2 of those matters within a single art unit. Practitioners should prioritize understanding the specific requirements of RICCI, CRAIG D, as his decisions affect 2 of the 3 pending cases. The focus on 1 art unit within the Biotechnology & Pharmaceuticals sector suggests that the company's innovations are being evaluated by a specific group at the patent office. Successfully navigating these 3 pending office actions will depend on the interactions with the 2 distinct examiners involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 2 | 53.5% | +52.7% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18760472 | 2-Thioxothiazolidine-4-One Derivatives And Their Uses | RICCI, CRAIG D | — |
| 18583535 | Phenothiazinyl Compounds and Uses | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18760472 | 2-Thioxothiazolidine-4-One Derivatives And Their Uses | RICCI, CRAIG D | — | §102 | Non-Final OA | — | Pending | Jul 01, 2024 |
| 18662524 | Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof | SHTERENGARTS, SAMANTHA L | — | §102DP | Non-Final OA | — | Pending | May 13, 2024 |
| 18583535 | Phenothiazinyl Compounds and Uses | RICCI, CRAIG D | 1611 | §102DP | Non-Final OA | — | Pending | Feb 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial